33852-43-6

Basic information

• Product Name: 3-METHOXY-2-NITROACETOPHENONE
• Synonyms: Ethanone, 1-(3-Methoxy-2-nitrophenyl)-
• CAS NO: 33852-43-6
• Molecular Formula: C₉H₉NO₄
• Molecular Weight: 195.17206
• Product Categories: Aromatic Acetophenones & Derivatives (substituted)
• Mol File: 33852-43-6.mol
• Article Data: 11

Chemical Properties

• Melting Point: 128.5-129.5 °C
• Boiling Point: 331.9 °C at 760 mmHg
• Flash Point: 159.6 °C
• Appearance: /
• Density: 1.244 g/cm³
• Storage Temp.: Sealed in dry,Room Temperature
• CAS DataBase Reference: 3-METHOXY-2-NITROACETOPHENONE(CAS DataBase Reference)
• NIST Chemistry Reference: 3-METHOXY-2-NITROACETOPHENONE(33852-43-6)
• EPA Substance Registry System: 3-METHOXY-2-NITROACETOPHENONE(33852-43-6)

Safety Data

• Hazardous Substances Data: 33852-43-6(Hazardous Substances Data)

Usage

General Description

3-Methoxy-2-nitroacetophenone is a chemical compound that belongs to the class of organic compounds known as phenylacetophenones. It is a yellow crystalline solid with the molecular formula C9H9NO4. 3-METHOXY-2-NITROACETOPHENONE is commonly used as an intermediate in the synthesis of various pharmaceuticals and agrochemicals. It is also known for its antibacterial and antifungal properties, making it useful in the development of new antimicrobial agents. Additionally, 3-Methoxy-2-nitroacetophenone is employed as a reagent in organic synthesis, particularly in the construction of complex organic molecules. Overall, this compound has a wide range of potential applications in both the pharmaceutical and agrochemical industries.

Upstream product

• 53967-72-9 1-(5-hydroxy-6-nitrophenyl)ethanone 
• 74-88-4 methyl iodide 
• 4920-80-3 3-methoxy-2-nitrobenzoic acid 
• 15865-57-3 2-nitro-3-methoxybenzoyl chloride 
• 105-53-3 diethyl malonate 
• 121-71-1 3-Hydroxyacetophenone 
• 53055-05-3 3-methoxy 2-nitrobenzaldehyde 
• 77-78-1 dimethyl sulfate 
• 195529-68-1 2-Nitro-3-(1-hydroxyethyl)anisole 
• 586-37-8 1-(3-Methoxyphenyl)ethanone 
• 99-03-6 1-(3-aminophenyl)ethanone 

Downstream Products

• 1204652-09-4 3-[2-chloro-3-(trifluoromethyl)phenyl]-1-(2,4-difluorobenzyl)-8-methoxycinnolin-4(1H)-one 
• 33844-20-1 3-bromo-8-methoxy-1H-cinnolin-4-one 
• 1204652-86-7 3-Bromo-1-(2,4-difluorobenzyl)-8-methoxycinnolin-4(1H)-one 
• 90417-27-9 8-methoxy-1H-cinnolin-4-one 
• 1026986-34-4 1-methoxy-2-nitro-3-(prop-1-en-2-yl)benzene 
• 1429782-06-8 C₁₁H₁₀Cl₃NO₃ 
• 953039-90-2 2-chloro-8-methoxy-4-methyl-quinazoline 
• 1187590-98-2 (2E)-1-(3-methoxy-2-nitrophenyl)-3-(4-methoxyphenyl)prop-2-en-1-one 
• 1026380-38-0 1-(2-Isopropyl-6-methoxy-phenyl)-3-pentyl-urea 
• 148726-46-9 1-(2-Hydroxy-6-isopropyl-phenyl)-3-pentyl-urea 

Relevant articles and documents

Design, synthesis, and biological evaluation of 4-Methyl quinazoline derivatives as anticancer agents simultaneously targeting phosphoinositide 3-kinases and histone deacetylases

Polypharmacology is a promising paradigm in modern drug discovery. Herein, we have discovered a series of novel PI3K and HDAC dual inhibitors in which the hydroxamic acid moiety as the zinc binding functional group was introduced to a quinazoline-based PI3K pharmacophore through an appropriate linker. Systematic structure-activity relationship studies resulted in lead compounds 23 and 36 that simultaneously inhibited PI3K and HDAC with nanomolar potencies and demonstrated favorable antiproliferative activities. Compounds 23 and 36 efficiently modulated the expression of p-AKT and Ac-H3, arrested the cell cycle, and induced apoptosis in HCT116 cancer cells. Following pharmacokinetic studies, 23 was further evaluated in HCT116 and HGC-27 xenograft models to show significant in vivo anticancer efficacies with tumor growth inhibitions of 45.8% (po, 150 mg/kg) and 62.6% (ip, 30 mg/kg), respectively. Overall, this work shows promise in discovering new anticancer therapeutics by the approach of simultaneously targeting PI3K and HDAC pathways with a single molecule.

SUBSTITUTED 1-ALKYLCINNOLIN-4(1H)-ONE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC APPLICATION OF SAME

The subject of the present invention is compounds corresponding to the formula (I) in which: X represents a divalent (C2-C5)alkylene radical which is unsubstituted or substituted one or more times by an Alk group; R1 represents a phenyl, a naphthyl, a pyridyl, a 1-benzothienyl or a 1,3-benzodioxolyl; R2 represents a hydrogen atom, a halogen atom, an Alk group, an OAlk group or else a group chosen from —S-Alk, —SO-Alk, —SO2-Alk, —CO—N(R4)-Alk, —N(R4)SO2-Alk, —N(R4)CO-Alk, —N(R4)SO2—N(Alk)2; R3 represents a hydrogen atom, a halogen atom, an Alk group or an OAlk group; R4 represents a hydrogen atom or a (C1-C4)alkyl; Alk represents an unsubstituted or substituted (C1-C4)alkyl. Preparation process and therapeutic application.

SUBSTITUTED 1-BENZYL-CINNOLIN-4(1H)-ONE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF

The present invention is related to novel substituted 1-benzylcinnolin-4(1H)-one derivatives having affinity for cannabinoid CB2 receptors, their preparation and their therapeutic application.